The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Artificial Kidney Global Market Report 2024, the artificial kidney market is expected to show promising growth in the forecast period.

Rapid Growth and Projections

• The artificial kidney market has witnessed significant expansion, surging from $9.22 billion in 2023 to $10.48 billion in 2024, with a CAGR of 13.7%.
• Factors driving this growth include increased prevalence of chronic kidney diseases (CKD), limited availability of donor organs, and advancements in renal replacement therapies.
• Projections indicate further growth to $16.74 billion by 2028, at a CAGR of 12.4%, fueled by rising healthcare investments, patient preference for home-based therapies, and global efforts to reduce dialysis dependency.

Surging Chronic Kidney Cases Propel Growth In The Artificial Kidney Market

• Chronic kidney disease (CKD) cases are rising globally, with an estimated 7.19 million affected individuals in the UK alone in 2023.
• Major companies like Fresenius SE, Medtronic Plc., and Baxter International Inc., among others, are key players driving the market.
• Artificial kidneys play a vital role in treating CKD by maintaining electrolyte balance and removing toxins from the body.

View More On The Artificial Kidney Market Report 2024 – https://www.thebusinessresearchcompany.com/report/artificial-kidney-global-market-report

Elevating Artificial Kidney Technology For Enhanced Patient Care

• Technological advancements are reshaping the artificial kidney market, with innovations like the Renova dialyzer reprocessing system.
• Renova, launched by NephroPlus, features cloud connectivity, enabling remote troubleshooting and enhancing patient care.
• Dialyzers such as Renova reduce infection risks, improve dialysis treatment quality, and efficiently remove toxins from the blood.

M42 Enhances Global Healthcare Presence With Acquisition Of Diaverum

• M42, a UAE-based healthcare company, acquired Diaverum in April 2023, strengthening its global healthcare footprint.
• The acquisition allows M42 to deliver innovative solutions worldwide and tap into Diaverum’s extensive clinic network.
• Diaverum, based in Sweden, specializes in providing dialysis services using advanced dialyzers.

Segmentation and Regional Insights

• The artificial kidney market is segmented by product type (wearable and implantable), dialysis (hemodialysis, peritoneal dialysis, combination), and end-users (hospitals, specialty clinics, ambulatory surgical centers, others).
• North America dominated the market in 2023, while the Asia-Pacific region is expected to witness the fastest growth in the forecast period.

Conclusion: A Glimpse into the Future of Healthcare

The artificial kidney market’s rapid expansion underscores the growing demand for innovative renal replacement therapies. With advancements in technology, patient care is being revolutionized, offering hope to millions suffering from chronic kidney diseases globally. As companies continue to invest in research and development, the landscape of kidney treatment is poised for remarkable transformation. As we march forward, collaborations, technological breakthroughs, and strategic acquisitions will shape the trajectory of the artificial kidney market, paving the way for a healthier future.

Request A Sample Of The Global Artificial Kidney Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=11881&type=smp